Background
In the present study, we investigated the prevalence of surveillance drug resistance mutations (SDRM) in individuals newly diagnosed with HIV who were starting ART in Brazil.
Methods
The WHO HIV Threshold Survey methodology was used. Subjects from six densely populated cities were selected, a sample representative of the Brazilian macro-regions. Blood samples were collected between October 2023 and November 2024 and transferred to a central laboratory for genotyping. HIV total DNA was extracted, and the pol gene’s Integrase, protease, and reverse transcriptase regions were amplified and sequenced. SDRM was evaluated according to the WHO Surveillance Drug Resistance Mutations List, an algorithm that excludes common polymorphisms
Results
We analyzed samples from 391 people with HIV in which 365 samples were successfully PCR amplified, from the cities of Brasilia (Central region, 68 samples), Manaus (North, 66 samples), Salvador (Northeast, 47 samples), São Paulo (Southeast, 54 samples), Santos (Southeast, 60 samples), and Porto Alegre (South, 70 samples). The overall prevalence of SDRM was 47 samples (12.9%). The prevalence of nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and integrase inhibitors SDRM was 11 (3.0%), 30 (8.2%), 7 (1.9%), and 4 (1.1%), respectively. Five (1.4%) presented with resistance to two classes. Doravirine-specific mutations were present in 11 (3%) people, conferring intermediate or high level resistance in 5 (1.4%) of them. Their impact on resistance will be further tested using phenotypic assays. The overall subtype profile at Protease/Reverse transcriptase was 65.9% B, 21.2% C, 8.9%, other/recombinants 4%, and at integrase was 66.5% B, 24.4% C, 7.9% F, and 1.2% others.
Conclusions
The overall prevalence of SDRM in Brazil was at intermediate levels. The prevalence of INSTI and Doravirine SDRMs nationwide was consistent with WHO guidelines to start therapy without prior resistance testing. Continuous and systematic vigilance is fundamental for formulating effective prevention and treatment strategies.
Table or Figure
